

# Development of siRNA therapeutics to target KRAS/G12D-mutant pancreatic cancer

Exollence Co., Ltd.



ONCOLOGY	Candidate
Product Type	Extracellular vesicles(EV) encapsulated with siRNA targeting KRAS/G12D mutation
Indication	Pancreatic Ductal Adeno Carcinoma
Target	Pancreatic cancer patients who have been identified as having a KRAS/G12D mutation
MoA(Mechanism of Action)	The siRNA designed to specifically target the KRAS G12D mutation degrades the mutant KRAS mRNA.
Competitiveness	<ul style="list-style-type: none"> <li>• Enhanced anti-tumor effects achieved by modification of siRNA (Proprietary patent)</li> <li>• Utilizing EVs as delivery vehicles to enhance biocompatibility and optimize delivery efficiency</li> <li>• Efficiently encapsulating siRNAs into extracellular vesicles (EVs) for a system that produces a huge quantity</li> </ul>
Development Stage	Candidate
Route of Administration	i.v. injection